Long-term efficacy and safety of dose-dense and dose-intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15-year follow-up of the ABVD DD-DI phase II study

We demonstrated that dose-densified and dose-intensified ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine; ABVD ) was safe and effective. Here, we present a post hoc long-term analysis of the 82 patients enrolled in the original study. The median observation time was 175 months (IQR 159-197)....

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2024-10, Vol.205 (4), p.1383
Main Authors: Corazzelli, Gaetano, Cuccaro, Annarosa, Morelli, Emanuela, Arcamone, Manuela, De Chiara, Annarosaria, Paccone, Andrea, Petrillo, Antonella, Ibello, Francesco, Aversa, Corrado, Esposito, Maria, Volzone, Francesco, Saggese, Mariangela, Capobianco, Gaetana, Sarno, Sabrina, Sirica, Letizia, Crisci, Stefania, De Filippi, Rosaria, Pinto, Antonio
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bleomycin - administration & dosage
Bleomycin - adverse effects
Bleomycin - therapeutic use
Dacarbazine - administration & dosage
Dacarbazine - adverse effects
Dacarbazine - therapeutic use
Doxorubicin - administration & dosage
Doxorubicin - adverse effects
Doxorubicin - therapeutic use
Female
Follow-Up Studies
Hodgkin Disease - drug therapy
Hodgkin Disease - mortality
Hodgkin Disease - radiotherapy
Humans
Male
Middle Aged
Treatment Outcome
Vinblastine - administration & dosage
Vinblastine - adverse effects
Vinblastine - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We demonstrated that dose-densified and dose-intensified ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine; ABVD ) was safe and effective. Here, we present a post hoc long-term analysis of the 82 patients enrolled in the original study. The median observation time was 175 months (IQR 159-197). At 15 years, progression-free and overall survival rates were 81.2% (95% CI, 69.9%-88.7%) and 92.7% (95% CI, 82.6%-97.0%), respectively. Four patients with multiple cardiovascular risk factors experienced delayed G3 cardiac events. The cumulative incidence of second malignancies at 20 years was 6.1%. Fertility and childbearing potential were unaffected. Data support an ongoing benefit for ABVD without uneven late toxicities.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.19646